Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports corporate governance changes. The report date is September 28, 2023, covering events occurring on September 26 and September 27, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes.
Material Changes
- Director Resignation: Marsha H. Fanucci resigned from the Board of Directors effective September 29, 2023.
- Committee Leadership: Upon Ms. Fanucci's resignation, Peter N. Kellogg assumed the role of Chair of the Audit Committee and is designated as an "audit committee financial expert."
- Board Size Reduction: The Board approved a reduction in its size from thirteen to twelve members, effective upon Ms. Fanucci's departure.
Management Commentary and Risks
Management stated that Ms. Fanucci's resignation was not caused by any disagreement with the Company regarding operations, policies, or practices. No financial risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of the Board size reduction (September 29, 2023).
- Verify Peter N. Kellogg's qualifications as the new Audit Committee Chair.
- Review subsequent filings for any impact on corporate governance or strategic direction.